A feasibility study of a new method for production of U-230/TH-226 fro alpha-immunotherapy applications

Targeted alpha therapy (TAT) is a novel cancer treatment modality, using alpha radiation to selectively destroy tumour cells. The principle of TAT is based on the coupling of alpha-emitting radionuclides to tumour selective carrier molecules, e.g. monoclonal antibodies or peptides, allowing the specific targeting of cancer cells. Due to the short path length of alpha particles in human tissue (b100 μm), TAT has the potential of delivering a highly cytotoxic radiation dose to targeted cancer cells, while limiting the damage to surrounding healthy tissue. Over the years, the Joint Research Centre of the European Commission has successfully developed various processes for the production and application of alpha emitters such as Ac-225/Bi-213, At-211 and U-230/Th- 226. This work describes a feasibility study of a new method for production of U-230 and Th-226 by helium-3 irradiation of Th-230 target material. The excitation function of the reaction Th-230(He-3,3n)U-230 has been measured for the first time and is compared to model calculations. A comparison to the establishedmethod for production of U-230 based proton irradiation of Th-232 is also presented.

ABBAS Kamel;  SIMONELLI Federica;  CYDZIK Izabela;  KOZEMPEL Jan;  APOSTOLIDIS Christos;  ZIELINSKA Barbara;  BRUCHERTSEIFER Frank;  MORGENSTERN Alfred; 

2011-11-03

ELSEVIER SCIENCE INC

JRC61211

0969-8051,   

https://publications.jrc.ec.europa.eu/repository/handle/JRC61211,   

10.1016/j.nucmedbio.2010.04.161,